Amylyx Pharmaceuticals, Inc. Expense Breakdown
No Expense Breakdown for AMLX on this site yet.
- 2026-06-30: Avexitide $9.36M; Other programs $4.63M; Amx0035 Psp $36.00K.
- 2025-06-30: Avexitide $7.11M; Other programs $4.76M; Amx0035 Psp $7.15M.
Source checked: the stored Expense Breakdown page for AMLX.
Expenses by product
Research and Development Expense (Excluding Acquired in Process Cost): each quarter (3 month)
| Quarter end | Avexitide | Other programs | Amx0035 Psp |
|---|---|---|---|
| 2026-06-30 | $9.36M | $4.63M | $36.00K |
| 2025-06-30 | $7.11M | $4.76M | $7.15M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |